Review Special Issues

Mechanisms and applications of the anti-inflammatory effects of photobiomodulation

  • Received: 05 April 2017 Accepted: 15 May 2017 Published: 19 May 2017
  • Photobiomodulation (PBM) also known as low-level level laser therapy is the use of red and near-infrared light to stimulate healing, relieve pain, and reduce inflammation. The primary chromophores have been identified as cytochrome c oxidase in mitochondria, and calcium ion channels (possibly mediated by light absorption by opsins). Secondary effects of photon absorption include increases in ATP, a brief burst of reactive oxygen species, an increase in nitric oxide, and modulation of calcium levels. Tertiary effects include activation of a wide range of transcription factors leading to improved cell survival, increased proliferation and migration, and new protein synthesis. There is a pronounced biphasic dose response whereby low levels of light have stimulating effects, while high levels of light have inhibitory effects. It has been found that PBM can produce ROS in normal cells, but when used in oxidatively stressed cells or in animal models of disease, ROS levels are lowered. PBM is able to up-regulate anti-oxidant defenses and reduce oxidative stress. It was shown that PBM can activate NF-kB in normal quiescent cells, however in activated inflammatory cells, inflammatory markers were decreased. One of the most reproducible effects of PBM is an overall reduction in inflammation, which is particularly important for disorders of the joints, traumatic injuries, lung disorders, and in the brain. PBM has been shown to reduce markers of M1 phenotype in activated macrophages. Many reports have shown reductions in reactive nitrogen species and prostaglandins in various animal models. PBM can reduce inflammation in the brain, abdominal fat, wounds, lungs, spinal cord.

    Citation: Michael R Hamblin. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation[J]. AIMS Biophysics, 2017, 4(3): 337-361. doi: 10.3934/biophy.2017.3.337

    Related Papers:

    [1] Marina Santiago, Lindsay Eysenbach, Jessica Allegretti, Olga Aroniadis, Lawrence J. Brandt, Monika Fischer, Ari Grinspan, Colleen Kelly, Casey Morrow, Martin Rodriguez, Majdi Osman, Zain Kassam, Mark B. Smith, Sonia Timberlake . Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study. AIMS Microbiology, 2019, 5(1): 1-18. doi: 10.3934/microbiol.2019.1.1
    [2] Alejandro Borrego-Ruiz, Juan J. Borrego . Human oral microbiome and its influence on mental health and brain disorders. AIMS Microbiology, 2025, 11(2): 242-294. doi: 10.3934/microbiol.2025013
    [3] Paola Brun . The profiles of dysbiotic microbial communities. AIMS Microbiology, 2019, 5(1): 87-101. doi: 10.3934/microbiol.2019.1.87
    [4] Sunarno Sunarno, Nelly Puspandari, Fitriana Fitriana, Uly Alfi Nikmah, Hasta Handayani Idrus, Novaria Sari Dewi Panjaitan . Extended spectrum beta lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae in Indonesia and South East Asian countries: GLASS Data 2018. AIMS Microbiology, 2023, 9(2): 218-227. doi: 10.3934/microbiol.2023013
    [5] Kerri Glassner, Eamonn MM Quigley, Lissa Franco, David W Victor III . Autoimmune liver disease and the enteric microbiome. AIMS Microbiology, 2018, 4(2): 334-346. doi: 10.3934/microbiol.2018.2.334
    [6] George L. Mendz, Nadeem O. Kaakoush, Julie A. Quinlivan . New techniques to characterise the vaginal microbiome in pregnancy. AIMS Microbiology, 2016, 2(1): 55-68. doi: 10.3934/microbiol.2016.1.55
    [7] Dawn B. Goldsmith, Zoe A. Pratte, Christina A. Kellogg, Sara E. Snader, Koty H. Sharp . Stability of temperate coral Astrangia poculata microbiome is reflected across different sequencing methodologies. AIMS Microbiology, 2019, 5(1): 62-76. doi: 10.3934/microbiol.2019.1.62
    [8] Rayane Chettaoui, Gilles Mayot, Loris De Almeida, Patrick Di Martino . Cranberry (Vaccinium macrocarpon) dietary supplementation and fecal microbiota of Wistar rats. AIMS Microbiology, 2021, 7(2): 257-270. doi: 10.3934/microbiol.2021016
    [9] Neetu Sharma, Sonu Bhatia, Abhinashi Singh Sodhi, Navneet Batra . Oral microbiome and health. AIMS Microbiology, 2018, 4(1): 42-66. doi: 10.3934/microbiol.2018.1.42
    [10] Srirengaraj Vijayaram, Karthikeyan Mahendran, Hary Razafindralambo, Einar Ringø, Suruli Kannan, Yun-Zhang Sun . Probiotics, gut microbiota, and brain health: Exploring therapeutic pathways. AIMS Microbiology, 2025, 11(3): 501-541. doi: 10.3934/microbiol.2025022
  • Photobiomodulation (PBM) also known as low-level level laser therapy is the use of red and near-infrared light to stimulate healing, relieve pain, and reduce inflammation. The primary chromophores have been identified as cytochrome c oxidase in mitochondria, and calcium ion channels (possibly mediated by light absorption by opsins). Secondary effects of photon absorption include increases in ATP, a brief burst of reactive oxygen species, an increase in nitric oxide, and modulation of calcium levels. Tertiary effects include activation of a wide range of transcription factors leading to improved cell survival, increased proliferation and migration, and new protein synthesis. There is a pronounced biphasic dose response whereby low levels of light have stimulating effects, while high levels of light have inhibitory effects. It has been found that PBM can produce ROS in normal cells, but when used in oxidatively stressed cells or in animal models of disease, ROS levels are lowered. PBM is able to up-regulate anti-oxidant defenses and reduce oxidative stress. It was shown that PBM can activate NF-kB in normal quiescent cells, however in activated inflammatory cells, inflammatory markers were decreased. One of the most reproducible effects of PBM is an overall reduction in inflammation, which is particularly important for disorders of the joints, traumatic injuries, lung disorders, and in the brain. PBM has been shown to reduce markers of M1 phenotype in activated macrophages. Many reports have shown reductions in reactive nitrogen species and prostaglandins in various animal models. PBM can reduce inflammation in the brain, abdominal fat, wounds, lungs, spinal cord.


    1. Introduction

    The Human Microbiome Project (HMP) launched in 2008 ushered in a new era of understanding the microbial communities residing with us. Until then, we did not realize that microorganisms outnumbered our cells by tenfold, and a great majority were unknown because they have yet to be cultured and studied [1]. The HMP enabled numerous results and insights into the intricate and important roles these microbes play in our health, ranging from metabolism and phenotype modulation (such as obesity), innate immune system development, to etiology for diseases or conditions (due to microbial ecosystem imbalance) [2,3]. New findings challenge our current thinking and approaches, and they prompt paradigm shift towards alternative solutions in disease diagnosis, prevention, and treatments.

    The HMP focused on five sites: gastrointestinal, oral, skin, nasal and urogenital. Urinary system was not part of the study because traditionally urine was considered sterile in healthy individuals [4,5,6,7,8]. This observation dated back to the mid 1800's when microbiology was still in its infancy and it continued to be upheld based on bacterial culturing outcomes. The clinical protocol and conditions for detection, however, only yield limited number and types of bacteria [4]. In the last few years with advanced culturing techniques and molecular approaches, we realized the urinary system contains extensive numbers and members of bacteria in healthy and asymptomatic individuals [9,10,11,12]. They are uniquely different than populations in the gut and vagina, two niches in close proximity from the bladder [5]. Their roles as urinary microbiota in maintaining our health and predisposing to a variety of diseases and disorders are just beginning to be elucidated [4,5,8,13,14].

    This review provides a general overview of urinary microbiome, its compositions and associations with different age and gender. The effects of these microbes in the health status are further illustrated by examples of diseases and disorders resulted from changes of microbial communities. The paper concludes with research gaps and future directions of urinary microbiome research.


    2. Microbiome in the Urinary System


    2.1. Urine is not sterile

    The clinical dogma, up to very recently, assumed urine from healthy individuals was sterile and the presence of bacteria signified some type of infection in the urinary tract [6]. As a body fluid, urine is hostile to the survival of microorganisms. It is hypertonic with low pH (average around pH 6), contains high concentration of urea which is inhibitory to most bacteria, and other substances including some that possess antimicrobial properties [13]. Additionally, the frequent flushing and voiding make persisting in the bladder difficult. Those that can survive, colonize and cause infection are termed uropathogens, and they often possess virulence factors such as host cell attachments, biofilm formation, host defense evasion, and antimicrobial resistance development [15]. Additional mechanisms to survive in this harsh environment include utilizing urine as substrate for growth, upregulating genes involved in iron transport, and devising systems to adapt in low pH, high urea concentrations and hypertonic environments [13].

    Another contributing factor to the long acceptance of urine as sterile was the clinical procedure for detecting bacteria in urine samples. Since the 1950's the gold standard for confirming urinary tract infection (UTI) has been the urine culture. Over the years, this detection method has proven questionable because the urine culture conditions are very restrictive, thus limits in the types of bacteria that are recoverable. The protocol specifies a very small amount of sample (1 μl of urine), plated only on two microbiological media (blood agar and MacConkey agar), and incubated at 35 ℃ for 24 hours. These culture conditions favor fast-growing aerobic bacteria and are designed for uropathogens such as Escherichia (E.) coli. Those that require special nutrient, takes more than 24 hours to grow, or prefer anaerobic environment (bladder is low in oxygen) are frequently missed from this screening [8,11,12,16]. Furthermore, the threshold to indicate a positive urine culture has been debated and changed throughout the years [17]. In general, 105 colony forming units (CFU)/mL indicate UTI; however, some urinary disorders resulted from lower number of organisms ( < 103 CFU/mL) are overlooked by this routine culture method [4,10,16,17].

    The advance of molecular techniques enabled a more comprehensive assessment of the microbes present in urine. The 16S ribosomal RNA gene sequence analysis yielded different types of bacteria in healthy urine [4,5,9,10]. In fact, the bladder may include resident bacteria flora such as Lactobacillus, Staphylococcus, Gardnerella, just to name a few [11,12,18]. One study reported a total of 321 genera from bladders of culture-negative women [12]. The disparity between culture and molecular assay prompted the development of Expanded Quantitative Urine Culture (EQUC) [10]. It uses more sample (10 μL or 100 μL) to plate on a variety of media, and incubate under different temperatures and atmospheric conditions [17,19]. A comparison between the clinical microbiology laboratory protocol and EQUC showed 90% false-negative rate for the former gold standard and missed 67% uropathogens overall [10,18,19,20]. Additionally, EQUC helps to determine many of the organisms identified by 16S rRNA gene sequencing are viable and cultivable under the appropriate growth conditions [4,7,10,20]. These findings led to the recommendation of a "streamlined EQUC" as a supplemental test for individuals suspected of UTI but had negative standard urine culture [19].

    These emerging evidences dispute that healthy bladder is sterile; rather, the bacterial community found in the urinary system has implications in the health status of an individual [5,8,10,11,21]. Although urine microbiome shared many similar genera with other sites in the body, it is less diverse and lower in number when compare with microbiome found in other physiological systems such as the gut and skin [18]. Nevertheless, the urinary tract is a unique environment niche for microbes, and the new knowledge associated with urinary microbiome opens door to better understanding of urinary system diseases, including implications in obstetrics and gynecology as expressed by a clinical opinion [11].


    2.2. Urinary microbiome among different populations


    2.2.1. Gender

    Studies have indicated the urinary microbiome is distinctive between men and women, likely due to differences in anatomical structures and hormones [5]. In general, females have a more heterogeneous mix of bacterial population than males in their clean catch mid-stream urine samples, reflecting the bladder microbiome determined by 16S rRNA analyses [9]. One study showed significantly higher number of E. coli cultured from healthy adult women (91%) than men (25%) [21]. Lactobacillus species are the most dominant members of urine microbiome in women during child bearing age [22]. Other microbiome identified by molecular method (16S rRNA gene sequencing) in female samples included representative members of the Actinobacteria (e.g., Actinomyces, Arthobacter) and Bacteroidetes (e.g., Bacteroides) phyla which were absent from male samples [9]. When considering the core microbiome with varied abundance in the urinary tract throughout life, both men and women possess three predominant genera-Lactobacillus, Corynebacterium, and Streptococcus [9,23,24].

    There were less reports regarding urinary microbiome in men. One study employing 16S rRNA gene sequencing to characterize bacterial communities in urine collected from adolescent men and found the predominant genera as Streptococcus, Gardnerella, Lactobacillus and Veillonella [23]. Another group investigated healthy urine microbiome in both men and women; using 16S rRNA gene sequencing and metaproteomic analyses they reported higher relative abundance of Corynebacterium in men [24]. This genus is considered a common superficial skin flora, and its members possibly residing in the proximal urethra and/or bladder as well as to the distal urethra. Additional findings were Enterococcus, Proteus, Klebsiella, and Aerococcusas more predominate in male urine.

    Variation of urinary microbiome between females and males may also stem from the different compositions in their urine. Women produce higher amount of citrate but less calcium and oxalate, whereas males excrete more creatinine [13]. The different constituents may favor certain microbes to survive in this niche, and they in turn contribute to the health status of their hosts. For example, women are more prone to UTI mostly due to anatomical reasons. However, there are evidences indicating microbes may also play a role in the occurring and recurring of UTI (see section 3.1), and their growth is likely promoted by certain substrates and hormones present in the female urine.


    2.2.2. Age

    Urine microbiome, similar to microbial communities in other physiological systems, changes with the individual's age [5]. Children and adults have different microbiome populations, likely due to urinary metabolites from diet change, personal hygiene and voiding habits. There are different bacterial genera within age groups among the adults [9]. Changes in hormones may have an influence in the microbiome [25]; a few studies indicated Lactobacillus species increased during puberty and decreased after menopause [4,5,19]. The microbiome could change in women who become pregnant, whereas those who are not pregnant seem to have more stable microbial compositions [22]. As one gets older, constipation and urinary incontinence may alter the survival and persistence of microbes. Symptoms of lower urinary tract seem more prevalent as people age [17]. Using molecular analyses (16S rRNA gene amplification), one study noted four genera were exclusive among the elderly (age 70+) irrespective of the gender: Jonquetella, Parvimonas, Proteiniphilum and Saccharofermentans [9]. These are not well known bacteria and only recently named. Common features among them include anaerobic and fastidious nutrient requirements which made cultivation by conventional methods difficult [26,27,28,29]. The implications of these organisms in the elderly urinary microbiome are still unknown and await further studies [5].

    The changes in urinary microbiome during one's lifetime have been associated with different diseases, and some will be further discussed in the next section. One example is the decrease of vaginal Lactobacillus spp. in women after menopausal allows colonization of uropathogens, resulting in increased UTI cases [30]. It is interesting to note that recurrent UTIs are not limited to older women; in fact, it is common among young and healthy women as well [31]. There are no obvious reasons for such observation, such as identifiable risk factors or abnormal urinary tracts associated with these occurrences [31]. Another example is catheter users who are at high risk of UTI. Catheter-associated urinary tract infection is a concern for the elderly as it is a common infection in nursing homes. Nevertheless, this type of infection also affects patients in acute care regardless of age [32]. Lastly, the bacteria Oxalobacter formigenes has been demonstrated with a possible role in urolithiasis (i.e., kidney stones) [33]. It's colonization in the gut seems to be age-dependent, present in children up to 8 years old and then starts to decline by age 12 into adulthood [5]. Urolithiasis cases are higher in adults, and some postulate the lower number of O. formigenes along with other factors may contribute to the increased concentration of oxalate in these individuals' urine [34,35].


    3. Association with Diseases and Disorders


    3.1. Urinary tract infection

    As the second most common type of infection, UTI accounts for approximately 8.1 million visits to the clinics in 2012 [31,36]. Among them women are more likely to encounter such infections due to anatomical structure (approximately 50% experience UTI in their lifetime), and the elderly with multiple risk factors (e.g., obstruction, poor hygiene, diet and fluid intake) [21]. According to the American Urological Association, an estimated 150 million UTIs occur annually worldwide costing $6 billion in health care [37]. Obviously this disease is wide spread and poses a significant burden to the financial and healthcare systems.

    The UTI is commonly associated with E. coli, and it has been implicated in >70% uncomplicated and 25-50% complicated cases [15]. The infection is frequently persistent, and with each UTI the risk of having recurrence increases. For example among women with UTI, 20-25% will develop recurrent infection and 3% within 6 months after treatment [25]. Although E. coli has been considered as the main uropathogen in UTI cases, a prospective study examined individuals with chronic lower urinary tract symptoms found additional organisms associated with these illnesses. Using EQUC and 16S rRNA gene sequencing methods, species of Enterococcus and Staphylococcus were frequently recovered in urine samples regardless of collection methods (clean catch midstream or by catheters) [17]. This suggests the spectrum of bacterial colonization in the urinary tract is broader than previously thought.

    There are two types of recurrent infection-relapse and reinfection. The former is caused by the same organism with a shorter interval (within 2 weeks) from the original infection. On the other hand, reinfection is considered a new episode of illness resulted from a different strain of bacteria, and each occurrence is separated by a month after antibiotic treatment [31]. These distinctions were often difficult to discern in the past; however, advanced molecular technologies for bacteria identification now enable strain differentiation which could aid in determining the type of recurrence. This suggests important clinical implications because relapsing infection may result from metabolic, functional or structural abnormalities; thus, requiring more extensive urological evaluation or longer antimicrobial therapy [31].

    Reinfection was thought to occur when virulent uropathogens gain entry into the urinary system or re-emerge from the bladder. Among the bacterial species, E. coli are responsible for 80-90% of community-acquired cases [31]. Other etiological agents reported are Staphylococcus saprophyticus, Enterococcus faecalis, Klebsiella pneumoniae, and Proteus mirabilis [12,17]. The EQUC recovered more types of uropathogens that would have been missed from standard culture, an important consideration when half of these microbes were not found in women with UTI symptoms [19]. Molecular techniques allow a wider spectrum of bacterial genomic sequences to be detected, some of these are fastidious or uncultured species [14,31]. As mentioned previously, a number of virulence factors are expressed to invade and colonize their host cells. Uropathogenic E. coli produce 2 types of fimbriae (or pili) that aim at specific receptors on the epithelial cells in the urinary system [31]. Furthermore, these pathogens may develop osmoadaptability to survive under the acidic environmental conditions [15].

    There are evidences indicating a reservoir of pathogens may exist in the urinary system, possibly due to frequent failure of antibiotics to completely eradicate uropathogens, or the reemergence of the same organism resulting in recurrent infections [31]. While other microbes residing in the urogenital system are disrupted by antibiotics, pathogens may penetrate deeper to persist and re-infect the host. As E. coli population increases resulting in reinfection, the proportion of Lactobacillus that normally resides in the urogenital system notably decreases [31]. Two species are predominant in healthy women: Lactobacillus (L.) crispatus and L. iners [12,18,19,20]. These organisms play an important role in maintaining the health of urinary tract as their metabolic byproducts (such as lactic acid, hydrogen peroxide) interfere with the adhesion of E. coli by downregulating some virulence factor expressions [5,15,31]. These results prompt replenishing lactobacilli as a strategy to manage recurrent UTIs, and probiotics have been considered due to promising results in maintaining a balanced microbiome in other physiological systems [38]. However, several clinical trials compared the effectiveness of probiotics versus antibiotics with inconclusive results [30]. Nevertheless, the general consensus is probiotic has merits over long term antibiotic treatments, the current method of managing UTIs, and warrants more research in this area. One of the main advantages is the lack of collateral damage, i.e., no increase in resistance rate, when a non-antibiotic prophylaxis is used. Several reports indicated high incidences (up to 100%) of resistance even among asymptomatic individuals when antibiotics were administered [5,30,31]. In some cases, persistence remained even after completion of the course [31].


    3.2. Urgency urine incontinence

    Urgency urinary incontinence (UUI) is a chronic condition that accounts for 1.5-22% of the US population, mostly affecting women and the elderly [16,20]. Although a proportion of cases resolve after some time, it poses a significant financial burden costing over $76 billion in 2015 [18].

    In spite of its prevalence, UUI is a poorly understood urinary condition often attributed to abnormal neuromuscular signaling or functioning [18,20]. Because the symptoms seem to overlap with UTI, it is plausible that microbiome also plays a significant role in UUI [16,18,25]. A prospective cohort study using both culturing (EQUC) and molecular (16S rRNA gene sequencing) methods showed more diversity in women affected by UUI [20]. With combined methods, others reported genera such as Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, and Oligella; many of which contain emerging uropathgoen members (e.g., Aeroccocus urinae, Oligella ureolytica) [11,18] There seems to be a correlation between symptom severity and microbial diversity, as a study using 16S rRNA gene sequencing found increased UUI symptom gravity associated with lower microbial types [25]. In several studies, both women with and without UUI showed Lactobacillus and Gardnerella as the two most dominant genera by molecular techniques; the former plays a protective role as mentioned above, but the latter often associated with bacterial vaginosis [4,14,23]. For Lactobacillus there is additional distinction at the species level-gasseri was more frequent from UUI samples but crispatus more readily encountered from the control [18]. It is unclear how these two species differ in their role in the urinary system. Additional genera recovered by molecular (16S rRNA) and culturing (EQUC) methods in the urinary microbiome are Bifidobacterium, Enterococcus, Actinomyces, Prevotella and Atopobium. These are also present in vaginal tracts which suggest the possibility of a shared urogenital microbiome [14,18]. The protective role of urine microbiome in the bladder and how they influence UUI warrant further studies.


    3.3. Urolithiasis

    The development of calcium oxalate stones, or urolithiasis, is one of the most common disorders of the urinary tract. It affects 8.8% of the population in the US, and over 300,000 people go to emergency room for such problem each year [39]. Calcium oxalate seems to be the most common type; specifically, oxalate has been reported in 75% of the urinary stones [33]. Oxalate is produced from amino acid metabolism; because it is toxic, it must be excreted by the kidney [33,40]. Epidemiological studies and animal models indicate a correlation between the oxalate excretion and kidney stone development; thus, decreasing dietary oxalate and calcium intake would likely reduce such risk [34].

    There have been several postulates regarding the interactions of microbiome and stone formation. One of the associations involved a bacterium, Oxalobacter (O.) formigenes, which was identified with a possible role in reducing recurrent calcium oxalate kidney stone formation [33]. As an anaerobic organism residing in human's intestine, it uses oxalate as main carbon and energy sources [40]. In fact, this bacterium degrades approximately 51% of the dietary oxalate per day and regulates the net intestinal transport of oxalate [41]. Consequently O. formigenes lowers the oxalate concentration for absorption in the colon which in turn decreases the amount excreted from the kidney [33]. As a case in point, colonization of O. formigenes resulted in 70% decrease in the risk of recurrent stone formation [5,34].

    Previously, O. formigenes was mostly detected by anaerobic culturing, a time consuming method with varying results. The advancement in molecular techniques (genome sequencing and 16S rRNA gene sequencing) enable more precise assessment of this organism in the microbiome. In the US, the prevalence of O. formigenes is relatively low (31% of population) in adults, perhaps stemmed from common antibiotic usage eliminating this bacterium from the gut [5,40]. This was supported by the absence of O. formigenes in women with recurrent UTI, their frequent antibiotic treatments likely attributed to the increase oxalate excretion. On the other hand, this bacterial population is stable for a period of time (at least up to six months) once colonized. Diets with high oxalate can induce O. formigenes, and there is an interplay between dietary calcium, oxalate and the colonization of O. formigenesthat result in urinary oxalate level of an individual [33,34]. Other organisms (e.g., species of Lactobacillus) have also been implicated in degrading oxalate. However, they are not as efficient as O. formigenes so they will not be further discussed

    Another interaction between microbiome and kidney stone was reported by Barr-Beare et al [42]. Although this study only involved 5 young patients, 16S rRNA sequencing and EQUC methods showed the kidney stones contained multiple bacterial taxa. The dominant type (80%) was Enterobacteriaceae, leading the authors to suggest possible association of this bacterial family with pediatric kidney stones. Furthermore, individuals with stones often have higher incidences of UTI. How this observation affects future treatments of both hypercalciuria (high calcium in urine) and UTI awaits additional studies.


    3.4. Bladder cancer

    Urothelial carcinoma, mostly affecting the bladder, is one of the most common cancers in the urinary system [43]. It accounted for approximately 77, 000 new cases with more than 16,000 deaths in 2016 [44]. Among the risk factors is chronic urinary tract infections especially in the bladder. Because microbiota have been involved in cancers of other organs, it is conceivable that they may play a role in urothelial carcinoma [5,43].

    One such study utilizing sequencing technology, albeit with a small sample size, showed the average genera found in cancer patients were noticeably higher than those healthy individuals (73.1 ± 42.8 versus 42.6 ± 19.4) [43]. Acinetobacter was the predominant genus and Streptococcus population was considerably elevated in cancer samples. These results indicate possible association between altered microbiota, both in population types and numbers, and urothelial carcinoma.

    On the other hand, microbiota in the bladder may be involved in the prevention of recurrent superficial bladder cancer [5]. Some evidences indicated L. casei could reduce superficial bladder cancer recurrence, leading to considerations in applying probiotics as an alternative therapy [5]. The mechanism of action and interactions of lactobacilli with different microbial populations, however, remain as knowledge gaps.


    4. Conclusion

    Assessing microbiome in the urinary system has been a recent development, after expanded culturing technique and molecular analyses disputed the traditional thinking that urine was sterile. This review provided an overview of urinary microbiome and highlighted microbial members play an important role in urinary health of individuals. Understanding urinary microbiome, therefore, allows a more holistic approach in the diagnosis, treatment, and prevention of diseases and disorders in this system [17,20].

    There are various gaps that await further studies in urinary microbiome; such as mechanism of colonization (both beneficial organisms and uropathogens), predisposition for disorders due to certain microbial species, and the interplay between diets, probiotics, and other microorganisms. Because of its proximity to other physiological niches, the association between urinary microbes and other microbiomes (gut, genital) may enable a comprehensive assessment of certain diseases (e.g., kidney stone, chronic kidney diseases, bladder cancer) [5,43]. An example is how carcinogens produced in the gut, filtered by the kidneys, and stored in the bladder prior to excretion influence urinary microbiota. A better understanding in these areas will aid in effective and more precise treatments in the future.

    Most of the studies cited in this review were conducted with 16S rRNA gene sequencing as their molecular analysis method. Although powerful, its utility in comprehensive assessments of microbiome has certain limitations. For incidence, primers designed from this genetic region specifically target bacteria and at times only capable of genus level identification [10]. On the other hand, whole genome sequencing and metagenomics analyses are highly sensitive in detecting organisms present in individuals. This was demonstrated by the study of Barnett et al. when assessing O. formigenes in healthy young adults [34]. Analyzing the complete genome content of a sample is also broader in scope and allows distinguishing members of the entire microbial communities including viruses, fungi, and parasites. It is even capable of detecting species that are low in numbers which may be overlooked by other molecular methods. Furthermore, the genomic data facilitate studies of genetic composition to understand how organisms respond to different environments (e.g., antibiotics, stress) and their mechanisms to colonize the urinary systems [41]. Next generation sequencing technology and deep sequencing will enable the elucidation of core microbial populations and ascertain their roles in the urinary tract system [43]. This information potentially could lead to early indicators for diseases and the development of diagnostic tests.

    Urinary microbiome research comes at the right time as a National Microbiome Initiative announced in 2016 aims at promoting integrated microbiome studies across different ecosystems by engaging interdisciplinary teams [45]. The Initiative also mentioned new platform technologies, among them is whole genomic sequencing which continues to advance significantly and its cost reduced considerably in recent years. This technology is no longer limited to big research and commercial laboratories. Bioinformatics capability has also expanded substantially to address the emergent needs of processing large amount of sequencing data and performing analysis in a timely manner. Numerous tools are being developed with many available as open source for use in the community. Opportunities and potential are plentiful for future studies in urinary microbiome.


    Conflict of Interest

    The author declares no conflict of interest in this paper.


    [1] Hamblin MR (2017) History of Low-Level Laser (Light) Therapy, In: Hamblin MR, de Sousa MVP, Agrawal T, Editors, Handbook of Low-Level Laser Therapy, Singapore: Pan Stanford Publishing.
    [2] Anders JJ, Lanzafame RJ, Arany PR (2015) Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg 33: 183–184. doi: 10.1089/pho.2015.9848
    [3] Hamblin MR, de Sousa MVP, Agrawal T (2017) Handbook of Low-Level Laser Therapy, Singapore: Pan Stanford Publishing.
    [4] de Freitas LF, Hamblin MR (2016) Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron 22: 348–364. doi: 10.1109/JSTQE.2016.2561201
    [5] Wang Y, Huang YY, Wang Y, et al. (2016) Photobiomodulation (blue and green light) encourages osteoblastic-differentiation of human adipose-derived stem cells: role of intracellular calcium and light-gated ion channels. Sci Rep 6: 33719. doi: 10.1038/srep33719
    [6] Wang L, Jacques SL, Zheng L (1995) MCML-Monte Carlo modeling of light transport in multi-layered tissues. Comput Meth Prog Bio 47: 131–146. doi: 10.1016/0169-2607(95)01640-F
    [7] Huang YY, Chen AC, Carroll JD, et al. (2009) Biphasic dose response in low level light therapy. Dose Response 7: 358–383.
    [8] Huang YY, Sharma SK, Carroll JD, et al. (2011) Biphasic dose response in low level light therapy-an update. Dose Response 9: 602–618. doi: 10.2203/dose-response.11-009.Hamblin
    [9] Mason MG, Nicholls P, Cooper CE (2014) Re-evaluation of the near infrared spectra of mitochondrial cytochrome c oxidase: Implications for non invasive in vivo monitoring of tissues. Biochim Biophys Acta 1837: 1882–1891. doi: 10.1016/j.bbabio.2014.08.005
    [10] Karu TI, Pyatibrat LV, Kolyakov SF, et al. (2005) Absorption measurements of a cell monolayer relevant to phototherapy: reduction of cytochrome c oxidase under near IR radiation. J Photochem Photobiol B 81: 98–106. doi: 10.1016/j.jphotobiol.2005.07.002
    [11] Karu TI (2010) Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life 62: 607–610. doi: 10.1002/iub.359
    [12] Wong-Riley MT, Liang HL, Eells JT, et al. (2005) Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem 280: 4761–4771. doi: 10.1074/jbc.M409650200
    [13] Lane N (2006) Cell biology: power games. Nature 443: 901–903. doi: 10.1038/443901a
    [14] Pannala VR, Camara AK, Dash RK (2016) Modeling the detailed kinetics of mitochondrial cytochrome c oxidase: Catalytic mechanism and nitric oxide inhibition. J Appl Physiol 121: 1196–1207. doi: 10.1152/japplphysiol.00524.2016
    [15] Fernandes AM, Fero K, Driever W, et al. (2013) Enlightening the brain: linking deep brain photoreception with behavior and physiology. Bioessays 35: 775–779. doi: 10.1002/bies.201300034
    [16] Poletini MO, Moraes MN, Ramos BC, et al. (2015) TRP channels: a missing bond in the entrainment mechanism of peripheral clocks throughout evolution. Temperature 2: 522–534. doi: 10.1080/23328940.2015.1115803
    [17] Caterina MJ, Pang Z (2016) TRP channels in skin biology and pathophysiology. Pharmaceuticals 9: 77. doi: 10.3390/ph9040077
    [18] Montell C (2011) The history of TRP channels, a commentary and reflection. Pflugers Arch 461: 499–506. doi: 10.1007/s00424-010-0920-3
    [19] Smani T, Shapovalov G, Skryma R, et al. (2015) Functional and physiopathological implications of TRP channels. Biochim Biophys Acta 1853: 1772–1782. doi: 10.1016/j.bbamcr.2015.04.016
    [20] Cronin MA, Lieu MH, Tsunoda S (2006) Two stages of light-dependent TRPL-channel translocation in Drosophila photoreceptors. J Cell Sci 119: 2935–2944. doi: 10.1242/jcs.03049
    [21] Sancar A (2000) Cryptochrome: the second photoactive pigment in the eye and its role in circadian photoreception. Annu Rev Biochem 69: 31–67. doi: 10.1146/annurev.biochem.69.1.31
    [22] Weber S (2005) Light-driven enzymatic catalysis of DNA repair: a review of recent biophysical studies on photolyase. Biochim Biophys Acta 1707: 1–23. doi: 10.1016/j.bbabio.2004.02.010
    [23] Gillette MU, Tischkau SA (1999) Suprachiasmatic nucleus: the brain's circadian clock. Recent Prog Horm Res 54: 33–58.
    [24] Kofuji P, Mure LS, Massman LJ, et al. (2016) Intrinsically photosensitive petinal ganglion cells (ipRGCs) are necessary for light entrainment of peripheral clocks. PLoS One 11: e0168651. doi: 10.1371/journal.pone.0168651
    [25] Sexton T, Buhr E, Van Gelder RN (2012) Melanopsin and mechanisms of non-visual ocular photoreception. J Biol Chem 287: 1649–1656. doi: 10.1074/jbc.R111.301226
    [26] Ho MW (2015) Illuminating water and life: Emilio Del Giudice. Electromagn Biol Med 34: 113–122. doi: 10.3109/15368378.2015.1036079
    [27] Inoue S, Kabaya M (1989) Biological activities caused by far-infrared radiation. Int J Biometeorol 33: 145–150. doi: 10.1007/BF01084598
    [28] Damodaran S (2015) Water at biological phase boundaries: its role in interfacial activation of enzymes and metabolic pathways. Subcell Biochem 71: 233–261. doi: 10.1007/978-3-319-19060-0_10
    [29] Chai B, Yoo H, Pollack GH (2009) Effect of radiant energy on near-surface water. J Phys Chem B 113: 13953–13958.
    [30] Pollack GH, Figueroa X, Zhao Q (2009) Molecules, water, and radiant energy: new clues for the origin of life. Int J Mol Sci 10: 1419–1429. doi: 10.3390/ijms10041419
    [31] Sommer AP, Haddad M, Fecht HJ (2015) Light effect on water viscosity: implication for ATP biosynthesis. Sci Rep 5: 12029. doi: 10.1038/srep12029
    [32] FDA (2016) Code of Federal Regulations 21CFR890.5500, Title 21, Vol 8.
    [33] Chen ACH, Huang YY, Arany PR, et al. (2009) Role of reactive oxygen species in low level light therapy. Proc SPIE 7165: 716502–716511. doi: 10.1117/12.814890
    [34] Chen AC, Arany PR, Huang YY, et al. (2011) Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One 6: e22453. doi: 10.1371/journal.pone.0022453
    [35] Sharma SK, Kharkwal GB, Sajo M, et al. (2011) Dose response effects of 810 nm laser light on mouse primary cortical neurons. Lasers Surg Med 43: 851–859. doi: 10.1002/lsm.21100
    [36] Tatmatsu-Rocha JC, Ferraresi C, Hamblin MR, et al. (2016) Low-level laser therapy (904 nm) can increase collagen and reduce oxidative and nitrosative stress in diabetic wounded mouse skin. J Photochem Photobiol B 164: 96–102. doi: 10.1016/j.jphotobiol.2016.09.017
    [37] De Marchi T, Leal Junior EC, Bortoli C, et al. (2012) Low-level laser therapy (LLLT) in human progressive-intensity running: effects on exercise performance, skeletal muscle status, and oxidative stress. Lasers Med Sci 27: 231–236. doi: 10.1007/s10103-011-0955-5
    [38] Fillipin LI, Mauriz JL, Vedovelli K, et al. (2005) Low-level laser therapy (LLLT) prevents oxidative stress and reduces fibrosis in rat traumatized Achilles tendon. Lasers Surg Med 37: 293–300. doi: 10.1002/lsm.20225
    [39] Huang YY, Nagata K, Tedford CE, et al. (2013) Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro. J Biophotonics 6: 829–838.
    [40] Hervouet E, Cizkova A, Demont J, et al. (2008) HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 29: 1528–1537. doi: 10.1093/carcin/bgn125
    [41] Madungwe NB, Zilberstein NF, Feng Y, et al. (2016) Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart. Am J Cardiovasc Dis 6: 93–108.
    [42] Martins DF, Turnes BL, Cidral-Filho FJ, et al. (2016) Light-emitting diode therapy reduces persistent inflammatory pain: Role of interleukin 10 and antioxidant enzymes. Neuroscience 324: 485–495. doi: 10.1016/j.neuroscience.2016.03.035
    [43] Macedo AB, Moraes LH, Mizobuti DS, et al. (2015) Low-level laser therapy (LLLT) in dystrophin-deficient muscle cells: effects on regeneration capacity, inflammation response and oxidative stress. PLoS One 10: e0128567. doi: 10.1371/journal.pone.0128567
    [44] Chen AC, Huang YY, Sharma SK, et al. (2011) Effects of 810-nm laser on murine bone-marrow-derived dendritic cells. Photomed Laser Surg 29: 383–389. doi: 10.1089/pho.2010.2837
    [45] Yamaura M, Yao M, Yaroslavsky I, et al. (2009) Low level light effects on inflammatory cytokine production by rheumatoid arthritis synoviocytes. Lasers Surg Med 41: 282–290. doi: 10.1002/lsm.20766
    [46] Hwang MH, Shin JH, Kim KS, et al. (2015) Low level light therapy modulates inflammatory mediators secreted by human annulus fibrosus cells during intervertebral disc degeneration in vitro. Photochem Photobiol 91: 403–410. doi: 10.1111/php.12415
    [47] Imaoka A, Zhang L, Kuboyama N, et al. (2014) Reduction of IL-20 expression in rheumatoid arthritis by linear polarized infrared light irradiation. Laser Ther 23: 109–114. doi: 10.5978/islsm.14-OR-08
    [48] Lim W, Choi H, Kim J, et al. (2015) Anti-inflammatory effect of 635 nm irradiations on in vitro direct/indirect irradiation model. J Oral Pathol Med 44: 94–102. doi: 10.1111/jop.12204
    [49] Choi H, Lim W, Kim I, et al. (2012) Inflammatory cytokines are suppressed by light-emitting diode irradiation of P. gingivalis LPS-treated human gingival fibroblasts: inflammatory cytokine changes by LED irradiation. Lasers Med Sci 27: 459–467.
    [50] Sakurai Y, Yamaguchi M, Abiko Y (2000) Inhibitory effect of low-level laser irradiation on LPS-stimulated prostaglandin E2 production and cyclooxygenase-2 in human gingival fibroblasts. Eur J Oral Sci 108: 29–34. doi: 10.1034/j.1600-0722.2000.00783.x
    [51] Nomura K, Yamaguchi M, Abiko Y (2001) Inhibition of interleukin-1beta production and gene expression in human gingival fibroblasts by low-energy laser irradiation. Lasers Med Sci 16: 218–223. doi: 10.1007/PL00011358
    [52] Briken V, Mosser DM (2011) Editorial: switching on arginase in M2 macrophages. J Leukoc Biol 90: 839–841. doi: 10.1189/jlb.0411203
    [53] Whyte CS, Bishop ET, Ruckerl D, et al. (2011) Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol 90: 845–854. doi: 10.1189/jlb.1110644
    [54] Xu H, Wang Z, Li J, et al. (2017) The polarization states of microglia in TBI: A new paradigm for pharmacological intervention. Neural Plast 2017: 5405104.
    [55] Lu J, Xie L, Liu C, et al. (2017) PTEN/PI3k/AKT regulates macrophage polarization in emphysematous mice. Scand J Immunol.
    [56] Saha B, Kodys K, Szabo G (2016) Hepatitis C virus-induced monocyte differentiation into polarized M2 macrophages promotes stellate cell activation via TGF-beta. Cell Mol Gastroenterol Hepatol 2: 302–316. doi: 10.1016/j.jcmgh.2015.12.005
    [57] Fernandes KP, Souza NH, Mesquita-Ferrari RA, et al. (2015) Photobiomodulation with 660-nm and 780-nm laser on activated J774 macrophage-like cells: Effect on M1 inflammatory markers. J Photochem Photobiol B 153: 344–351.
    [58] Silva IH, de Andrade SC, de Faria AB, et al. (2016) Increase in the nitric oxide release without changes in cell viability of macrophages after laser therapy with 660 and 808 nm lasers. Lasers Med Sci 31: 1855–1862. doi: 10.1007/s10103-016-2061-1
    [59] von Leden RE, Cooney SJ, Ferrara TM, et al. (2013) 808 nm wavelength light induces a dose-dependent alteration in microglial polarization and resultant microglial induced neurite growth. Lasers Surg Med 45: 253–263. doi: 10.1002/lsm.22133
    [60] Sousa KB, de Santana Araujo L, Pedroso NM, et al. (2017) Photobiomodulation effects on gene and protein expression of proinflammatory chemokines and cytokines by J774 macrophages polarized to M1 phenotype. Lasers Surg Med 49: 36.
    [61] de Lima FJ, de Oliveira Neto OB, Barbosa FT, et al. (2016) Is there a protocol in experimental skin wounds in rats using low-level diode laser therapy (LLDLT) combining or not red and infrared wavelengths? Systematic review. Lasers Med Sci 31: 779–787.
    [62] Tchanque-Fossuo CN, Ho D, Dahle SE, et al. (2016) Low-level light therapy for treatment of diabetic foot ulcer: a review of clinical experiences. J Drugs Dermatol 15: 843–848.
    [63] Gupta A, Keshri GK, Yadav A, et al. (2015) Superpulsed (Ga-As, 904 nm) low-level laser therapy (LLLT) attenuates inflammatory response and enhances healing of burn wounds. J Biophotonics 8: 489–501. doi: 10.1002/jbio.201400058
    [64] Weylandt KH, Chiu CY, Gomolka B, et al. (2012) Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostag Oth Lipid M 97: 73–82. doi: 10.1016/j.prostaglandins.2012.01.005
    [65] Tang Y, Zhang MJ, Hellmann J, et al. (2013) Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62: 618–627. doi: 10.2337/db12-0684
    [66] Bohr S, Patel SJ, Sarin D, et al. (2013) Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model. Wound Repair Regen 21: 35–43. doi: 10.1111/j.1524-475X.2012.00853.x
    [67] Castano AP, Dai T, Yaroslavsky I, et al. (2007) Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time. Lasers Surg Med 39: 543–550. doi: 10.1002/lsm.20516
    [68] Moriyama Y, Moriyama EH, Blackmore K, et al. (2005) In vivo study of the inflammatory modulating effects of low-level laser therapy on iNOS expression using bioluminescence imaging. Photochem Photobiol 81: 1351–1355. doi: 10.1562/2005-02-28-RA-450
    [69] Pallotta RC, Bjordal JM, Frigo L, et al. (2012) Infrared (810-nm) low-level laser therapy on rat experimental knee inflammation. Lasers Med Sci 27: 71–78. doi: 10.1007/s10103-011-0906-1
    [70] Ferraresi C, Hamblin MR, Parizotto NA (2012) Low-level laser (light) therapy (LLLT) on muscle tissue: performance, fatigue and repair benefited by the power of light. Photonics Lasers Med 1: 267–286.
    [71] Ferraresi C, Huang YY, Hamblin MR (2016) Photobiomodulation in human muscle tissue: an advantage in sports performance? J Biophotonics.
    [72] Ferraresi C, de Sousa MV, Huang YY, et al. (2015) Time response of increases in ATP and muscle resistance to fatigue after low-level laser (light) therapy (LLLT) in mice. Lasers Med Sci 30: 1259–1267. doi: 10.1007/s10103-015-1723-8
    [73] Silveira PC, Scheffer Dda L, Glaser V, et al. (2016) Low-level laser therapy attenuates the acute inflammatory response induced by muscle traumatic injury. Free Radic Res 50: 503–513. doi: 10.3109/10715762.2016.1147649
    [74] Pires de Sousa MV, Ferraresi C, Kawakubo M, et al. (2016) Transcranial low-level laser therapy (810 nm) temporarily inhibits peripheral nociception: photoneuromodulation of glutamate receptors, prostatic acid phophatase, and adenosine triphosphate. Neurophotonics 3: 015003. doi: 10.1117/1.NPh.3.1.015003
    [75] de Sousa MV, Ferraresi C, de Magalhaes AC, et al. (2014) Building, testing and validating a set of home-made von Frey filaments: A precise, accurate and cost effective alternative for nociception assessment. J Neurosci Methods 232: 1–5. doi: 10.1016/j.jneumeth.2014.04.017
    [76] Kobiela Ketz A, Byrnes KR, Grunberg NE, et al. (2016) Characterization of Macrophage/Microglial activation and effect of photobiomodulation in the spared nerve injury model of neuropathic pain. Pain Med: pnw144.
    [77] Decosterd I, Woolf CJ (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87: 149–158. doi: 10.1016/S0304-3959(00)00276-1
    [78] de Lima FM, Vitoretti L, Coelho F, et al. (2013) Suppressive effect of low-level laser therapy on tracheal hyperresponsiveness and lung inflammation in rat subjected to intestinal ischemia and reperfusion. Lasers Med Sci 28: 551–564. doi: 10.1007/s10103-012-1088-1
    [79] Silva VR, Marcondes P, Silva M, et al. (2014) Low-level laser therapy inhibits bronchoconstriction, Th2 inflammation and airway remodeling in allergic asthma. Respir Physiol Neurobiol 194: 37–48. doi: 10.1016/j.resp.2014.01.008
    [80] Rigonato-Oliveira N, Brito A, Vitoretti L, et al. (2017) Effect of low-level laser therapy on chronic lung inflammation in experimental model of asthma: A comparative study of doses. Lasers Surg Med 49: 36.
    [81] Huang YY, Gupta A, Vecchio D, et al. (2012) Transcranial low level laser (light) therapy for traumatic brain injury. J Biophotonics 5: 827–837. doi: 10.1002/jbio.201200077
    [82] Thunshelle C, Hamblin MR (2016) Transcranial low-level laser (light) therapy for brain injury. Photomed Laser Surg 34: 587–598. doi: 10.1089/pho.2015.4051
    [83] Hamblin MR (2016) Shining light on the head: Photobiomodulation for brain disorders. BBA Clin 6: 113–124. doi: 10.1016/j.bbacli.2016.09.002
    [84] Khuman J, Zhang J, Park J, et al. (2012) Low-level laser light therapy improves cognitive deficits and inhibits microglial activation after controlled cortical impact in mice. J Neurotrauma 29: 408–417. doi: 10.1089/neu.2010.1745
    [85] Veronez S, Assis L, Del Campo P, et al. (2017) Effects of different fluences of low-level laser therapy in an experimental model of spinal cord injury in rats. Lasers Med Sci 32: 343–349. doi: 10.1007/s10103-016-2120-7
    [86] Muili KA, Gopalakrishnan S, Eells JT, et al. (2013) Photobiomodulation induced by 670 nm light ameliorates MOG35-55 induced EAE in female C57BL/6 mice: a role for remediation of nitrosative stress. PLoS One 8: e67358. doi: 10.1371/journal.pone.0067358
    [87] Yoshimura TM, Sabino CP, Ribeiro MS (2016) Photobiomodulation reduces abdominal adipose tissue inflammatory infiltrate of diet-induced obese and hyperglycemic mice. J Biophotonics 9: 1255–1262. doi: 10.1002/jbio.201600088
    [88] Bjordal JM, Lopes-Martins RA, Iversen VV (2006) A randomised, placebo controlled trial of low level laser therapy for activated Achilles tendinitis with microdialysis measurement of peritendinous prostaglandin E2 concentrations. Br J Sports Med 40: 76–80. doi: 10.1136/bjsm.2005.020842
    [89] Hofling DB, Chavantes MC, Juliano AG, et al. (2010) Low-level laser therapy in chronic autoimmune thyroiditis: a pilot study. Lasers Surg Med 42: 589–596. doi: 10.1002/lsm.20941
    [90] Hofling DB, Chavantes MC, Juliano AG, et al. (2013) Low-level laser in the treatment of patients with hypothyroidism induced by chronic autoimmune thyroiditis: a randomized, placebo-controlled clinical trial. Lasers Med Sci 28: 743–753. doi: 10.1007/s10103-012-1129-9
    [91] Hofling DB, Chavantes MC, Juliano AG, et al. (2012) Assessment of the effects of low-level laser therapy on the thyroid vascularization of patients with autoimmune hypothyroidism by color Doppler ultrasound. ISRN Endocrinol 2012: 126720.
    [92] Hofling DB, Chavantes MC, Acencio MM, et al. (2014) Effects of low-level laser therapy on the serum TGF-beta1 concentrations in individuals with autoimmune thyroiditis. Photomed Laser Surg 32: 444–449. doi: 10.1089/pho.2014.3716
    [93] Hofling D, Chavantes MC, Buchpiguel CA, et al. (2017) Long-term follow-up of patients with hypothyroidism induced by autoimmune thyroiditis submitted to low-level laser therapy. Lasers Surg Med 49: 36.
    [94] Ferraresi C, Beltrame T, Fabrizzi F, et al. (2015) Muscular pre-conditioning using light-emitting diode therapy (LEDT) for high-intensity exercise: a randomized double-blind placebo-controlled trial with a single elite runner. Physiother Theory Pract: 1–8.
    [95] Ferraresi C, Dos Santos RV, Marques G, et al. (2015) Light-emitting diode therapy (LEDT) before matches prevents increase in creatine kinase with a light dose response in volleyball players. Lasers Med Sci 30: 1281–1287. doi: 10.1007/s10103-015-1728-3
    [96] Pinto HD, Vanin AA, Miranda EF, et al. (2016) Photobiomodulation therapy improves performance and accelerates recovery of high-level rugby players in field test: A randomized, crossover, double-blind, placebo-controlled clinical study. J Strength Cond Res 30: 3329–3338. doi: 10.1519/JSC.0000000000001439
    [97] Ferraresi C, Bertucci D, Schiavinato J, et al. (2016) Effects of light-emitting diode therapy on muscle hypertrophy, gene expression, performance, damage, and delayed-onset muscle soreness: case-control study with a pair of identical twins. Am J Phys Med Rehabil 95: 746–757. doi: 10.1097/PHM.0000000000000490
    [98] Johnston A, Xing X, Wolterink L, et al. (2016) IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol.
    [99] Ablon G (2010) Combination 830-nm and 633-nm light-emitting diode phototherapy shows promise in the treatment of recalcitrant psoriasis: preliminary findings. Photomed Laser Surg 28: 141–146. doi: 10.1089/pho.2009.2484
    [100] Choi M, Na SY, Cho S, et al. (2011) Low level light could work on skin inflammatory disease: a case report on refractory acrodermatitis continua. J Korean Med Sci 26: 454–456. doi: 10.3346/jkms.2011.26.3.454
    [101] Hamblin MR (2013) Can osteoarthritis be treated with light? Arthritis Res Ther 15: 120. doi: 10.1186/ar4354
    [102] Ip D (2015) Does addition of low-level laser therapy (LLLT) in conservative care of knee arthritis successfully postpone the need for joint replacement? Lasers Med Sci 30: 2335–2339. doi: 10.1007/s10103-015-1814-6
    [103] Brosseau L, Robinson V, Wells G, et al. (2005) Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis. Cochrane Database Syst Rev 19: CD002049.
    [104] Brosseau L, Welch V, Wells G, et al. (2004) Low level laser therapy (Classes I, II and III) for treating osteoarthritis. Cochrane Database Syst Rev: CD002046.
    [105] Barabas K, Bakos J, Zeitler Z, et al. (2014) Effects of laser treatment on the expression of cytosolic proteins in the synovium of patients with osteoarthritis. Lasers Surg Med 46: 644–649. doi: 10.1002/lsm.22268
    [106] Gregoriou S, Papafragkaki D, Kontochristopoulos G, et al. (2010) Cytokines and other mediators in alopecia areata. Mediators Inflamm 2010: 928030.
    [107] Avci P, Gupta GK, Clark J, et al. (2014) Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med 46: 144-151. doi: 10.1002/lsm.22170
    [108] Gupta AK, Foley KA (2017) A critical assessment of the evidence for low-level laser therapy in the treatment of hair loss. Dermatol Surg 43: 188–197. doi: 10.1097/DSS.0000000000000904
    [109] Yamazaki M, Miura Y, Tsuboi R, et al. (2003) Linear polarized infrared irradiation using Super Lizer is an effective treatment for multiple-type alopecia areata. Int J Dermatol 42: 738–740. doi: 10.1046/j.1365-4362.2003.01968.x
  • This article has been cited by:

    1. Xingxing Huang, Ting Pan, Lili Yan, Ting Jin, Ruonan Zhang, Bi Chen, Jiao Feng, Ting Duan, Yu Xiang, Mingming Zhang, Xiaying Chen, Zuyi Yang, Wenzheng Zhang, Xia Ding, Tian Xie, Xinbing Sui, The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer, 2020, 23523042, 10.1016/j.gendis.2020.10.002
    2. Ghiles Grine, Romain Lotte, David Chirio, Alicia Chevalier, Didier Raoult, Michel Drancourt, Raymond Ruimy, Co-culture of Methanobrevibacter smithii with enterobacteria during urinary infection, 2019, 43, 23523964, 333, 10.1016/j.ebiom.2019.04.037
    3. Andreia R. Yamanaka, Alessandra T. Hayakawa, Ícaro S. M. Rocha, Valéria Dutra, Valeria R. F. Souza, José N. Cruz, Lázaro M. Camargo, Luciano Nakazato, The Occurrence of Multidrug Resistant Bacteria in the Urine of Healthy Dogs and Dogs with Cystitis, 2019, 9, 2076-2615, 1087, 10.3390/ani9121087
    4. Christina M. Coleman, Daneel Ferreira, Oligosaccharides and Complex Carbohydrates: A New Paradigm for Cranberry Bioactivity, 2020, 25, 1420-3049, 881, 10.3390/molecules25040881
    5. Shaokai Zheng, Dario Carugo, Ali Mosayyebi, Ben Turney, Fiona Burkhard, Dirk Lange, Dominik Obrist, Sarah Waters, Francesco Clavica, Fluid mechanical modeling of the upper urinary tract, 2021, 2692-9368, 10.1002/wsbm.1523
    6. Jennifer F. Wu, Amutha Muthusamy, Gabriel A. Al-Ghalith, Dan Knights, Bin Guo, Baolin Wu, Rory P. Remmel, David P. Schladt, Maria-Luisa Alegre, William S. Oetting, Pamala A. Jacobson, Ajay K. Israni, Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients, 2018, 32, 09020063, e13436, 10.1111/ctr.13436
    7. Jennifer Jones, Craig P. Murphy, Roy D. Sleator, Eamonn P. Culligan, The urobiome, urinary tract infections, and the need for alternative therapeutics, 2021, 161, 08824010, 105295, 10.1016/j.micpath.2021.105295
    8. T. Sklyar, V. Gavryliuk, K. Lavrentievа, N. Kurahina, T. Lykholat, K. Zaichenko, M. Papiashvili, O. Lykholat, D. Stepansky, Monitoring of distribution of antibiotic-resistant strains of microorganisms in patients with dysbiosis of the urogenital tract , 2021, 12, 2520-2588, 199, 10.15421/022128
    9. Ali Zarei, Hossein Javid, Sara Sanjarian, Sara Senemar, Hanieh Zarei, Metagenomics studies for the diagnosis and treatment of prostate cancer, 2022, 82, 0270-4137, 289, 10.1002/pros.24276
    10. Shehani Jayalath, Dhammika Magana-Arachchi, Dysbiosis of the Human Urinary Microbiome and its Association to Diseases Affecting the Urinary System, 2022, 62, 0046-8991, 153, 10.1007/s12088-021-00991-x
    11. Hirak Ranjan Dash, Surajit Das, 2022, 118, 9780323989657, 91, 10.1016/bs.aambs.2022.02.002
    12. Hae Do Jung, Joo Yong Lee, Impact of the Human Microbiome on Nephrolithiasis, 2021, 16, 2465-8243, 25, 10.14777/uti.2021.16.2.25
    13. Rigoberto Pallares-Mendez, Daniel E. Cervantes-Miranda, Alejandro Diaz Gonzalez-Colmenero, Mario A. Ochoa-Arvizo, Adrian Gutierrez-Gonzalez, A Perspective of the Urinary Microbiome in Lower Urinary Tract Infections — A Review, 2022, 23, 1527-2737, 235, 10.1007/s11934-022-01108-7
    14. Rachael C. Wilkinson, 2022, 9780323903035, 306, 10.1016/B978-0-12-818731-9.00055-0
    15. Junjie Qin, Xulian Shi, Junming Xu, Simin Yuan, Bo Zheng, Enpu Zhang, Guixiao Huang, Guo Li, Ganggang Jiang, Shan Gao, Cheng Tian, Ruochun Guo, Zhicong Fu, Qingru Huang, Rentao Yang, Wenyong Zhang, Shenghui Li, Song Wu, Characterization of the Genitourinary Microbiome of 1,165 Middle-Aged and Elderly Healthy Individuals, 2021, 12, 1664-302X, 10.3389/fmicb.2021.673969
    16. Jonathan Josephs-Spaulding, Thøger Jensen Krogh, Hannah Clara Rettig, Mark Lyng, Mariam Chkonia, Silvio Waschina, Simon Graspeuntner, Jan Rupp, Jakob Møller-Jensen, Christoph Kaleta, Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs, 2021, 11, 2235-2988, 10.3389/fcimb.2021.562525
    17. Sigit Widadi, Hanifah Rahmi Fajrin, , 2022, Integration of Uroflowmetry and Database Applications Using Wireless Connection, 978-1-6654-6541-0, 369, 10.1109/ICE3IS56585.2022.10010145
    18. Mangesh Suryavanshi, Mukesh Poddar, Rekha Punchappady-Devasya, 2021, Chapter 12, 978-981-16-5616-3, 253, 10.1007/978-981-16-5617-0_12
    19. Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Michelangelo Fiorentino, Giovanni Brandi, Francesco Massari, Microbiota and prostate cancer, 2022, 86, 1044579X, 1058, 10.1016/j.semcancer.2021.09.007
    20. Xushen Chen, Ying Cheng, Xiaolin Tian, Jia Li, Xiaodong Ying, Qiuyi Zhao, Meng Wang, Yan Liu, Yulan Qiu, Xiaoyan Yan, Xuefeng Ren, Urinary microbiota and metabolic signatures associated with inorganic arsenic-induced early bladder lesions, 2023, 259, 01476513, 115010, 10.1016/j.ecoenv.2023.115010
    21. Marica Colella, Skender Topi, Raffaele Palmirotta, Donato D’Agostino, Ioannis Alexandros Charitos, Roberto Lovero, Luigi Santacroce, An Overview of the Microbiota of the Human Urinary Tract in Health and Disease: Current Issues and Perspectives, 2023, 13, 2075-1729, 1486, 10.3390/life13071486
    22. Yoon Jae Cho, Bokyoung Shin, Sung-Ha Lee, Sangmin Park, Yoon-Keun Kim, Jae-Jin Kim, Eunjoo Kim, Altered Urine Microbiome in Male Children and Adolescents with Attention-Deficit Hyperactivity Disorder, 2023, 11, 2076-2607, 2063, 10.3390/microorganisms11082063
    23. Bernardita M. Ljubetic, Ashu Mohammad, Butool Durrani, Amy D. Dobberfuhl, Pathophysiologic Insights into the Transition from Asymptomatic Bacteriuria to Urinary Tract Infection, 2023, 1527-2737, 10.1007/s11934-023-01183-4
    24. Elham Emami, Catherine MT Sherwin, Saeid Heidari-Soureshjani, Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis, 2024, 19, 27724328, 111, 10.2174/2772432817666220501114505
    25. Kishore Kumar Godisela, Pallaval Veera Bramhachari, 2023, Chapter 11, 978-981-99-5113-0, 205, 10.1007/978-981-99-5114-7_11
    26. Joie Ling, Andrew J. Hryckowian, Anthony R. Richardson, Re-framing the importance of Group B Streptococcus as a gut-resident pathobiont , 2024, 0019-9567, 10.1128/iai.00478-23
    27. Magdalena Jendraszak, Izabela Skibińska, Małgorzata Kotwicka, Mirosław Andrusiewicz, The elusive male microbiome: revealing the link between the genital microbiota and fertility. Critical review and future perspectives, 2024, 1040-8363, 1, 10.1080/10408363.2024.2331489
    28. Patrick Joubran, Françoise A. Roux, Matteo Serino, Jack-Yves Deschamps, Gut and Urinary Microbiota in Cats with Kidney Stones, 2024, 12, 2076-2607, 1098, 10.3390/microorganisms12061098
    29. Abdolah Razi, Azita Ghiaei, Fahimeh Kamali Dolatabadi, Ramin Haghighi, Unraveling the association of bacteria and urinary stones in patients with urolithiasis: an update review article, 2024, 11, 2296-858X, 10.3389/fmed.2024.1401808
    30. Amal Naji, Drew Siskin, Michael H Woodworth, John R Lee, Colleen S Kraft, Nirja Mehta, The Role of the Gut, Urine, and Vaginal Microbiomes in the Pathogenesis of Urinary Tract Infection in Women and Consideration of Microbiome Therapeutics, 2024, 11, 2328-8957, 10.1093/ofid/ofae471
    31. Pallabi Chatterjee, Isra Aman Aziz, Amarjit Singh, Aditi Singh, 2024, 9789815274431, 1, 10.2174/9789815274431124010003
    32. Jayaprakash Sasikumar, Rumaisa Ali Ebrahim, Shankar Prasad Das, Diverse Colonisation and Disease Associations of the Human Commensal Malassezia: Our Body's Secret Tenant, 2025, 68, 0933-7407, 10.1111/myc.70014
    33. Yasir Bukhari, Ryan Chow, Alexander Jie Xiang, Nucelio Lemos, Long-Term Antibiotics for Disturbed Bladder Microbiome Disorders, 2025, 0937-3462, 10.1007/s00192-025-06145-7
    34. Agnieszka Pastuszka, Szymon Tobor, Igor Łoniewski, Anna Wierzbicka-Woś, Katarzyna Sielatycka, Daniel Styburski, Danuta Cembrowska-Lech, Tomasz Koszutski, Marek Kurowicz, Klaudia Korlacka, Albert Podkówka, Artur Lemiński, Andrzej Brodkiewicz, Lidia Hyla-Klekot, Karolina Skonieczna-Żydecka, Rewriting the urinary tract paradigm: the urobiome as a gatekeeper of host defense, 2025, 52, 0301-4851, 10.1007/s11033-025-10609-w
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(52793) PDF downloads(4513) Cited by(724)

Article outline

Figures and Tables

Figures(7)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog